BIOLASE, the global leader in dental lasers, features groundbreaking periodontal protocol at Europerio 8

 BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that its groundbreaking REPaiR periodontal protocol will be part of the scientific programme at Europerio 8, the world’s leading conference in periodontology and implant dentistry. The triennial conference organized by the European Federation of Periodontologytakes place in London June 3 – 6, 2015 and attracts leading periodontists from more than 29 European countries.

REPaiR, Regenerative Er,Cr: YSGG Periodontitis Regimen, was developed by a team of leading periodontists from around the world in conjunction with BIOLASE and is supported by clinical research and meaningful patient outcomes. The REPaiR protocol is the first definitive step-by-step protocol for using an Er,Cr:YSGG laser to assist in the management of moderate and severe chronic periodontitis. REPaiR can be applied for total mouth periodontal treatment, or in a site-specific manner.

Presentation of the REPaiR protocol to members of the European Federation of Periodontology (EFP) supports the prestigious group’s awareness initiative. The EFP is strongly advocating that periodontal disease should be acknowledged as a major public health issue and for all dental and health professionals to act in the prevention, early diagnosis, and effective treatment of periodontal disease in order to combat the devastating oral and general health effects for the individual and society.

“What the EFP is doing in terms of leading the world in addressing periodontal disease is phenomenal. They have gone as far as creating a manifesto as a call to action to address this pressing global health concern. That I am able to participate and contribute to this movement for greater public health is extremely meaningful to me,” stated Samuel B. Low, D.D.S., M.S., M.Ed., Professor Emeritus, University of Florida, College of Dentistry, past President of the American Academy of Periodontology, and a principle developer of REPaiR.

Dr. Rana Al-Falaki, BDS, MFDS RCSI, MClinDent; MRD RCS, a leading London periodontist will be presenting the REPaiR protocol. Additionally, Dr. Samuel B. Low will be presenting on the topic entitled Innovative Closed Crown Lengthening with Micro Invasive Laser.

Compared to conventional methods employed to treat periodontitis, these speakers will present findings that support that the minimally invasive REPaiR laser protocol offers significant advantages, including:

  • Reduces pain and discomfort compared to conventional treatment
  • Promotes more rapid healing
  • Promotes cementum mediated periodontal ligament new-attachment to the root surface in the absence of long junctional epithelium
  • Expands treatment options for preserving tissue and bone

Visit BIOLASE at the Europerio meeting to learn more about how WaterLase iPlus 2.0 can help your practice grow with REPaiR.

About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company’s proprietary laser products incorporate approximately 250 patented and 100 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 27,600 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

RELATED NEWS

RESOURCES